CMS keeps 2010 OPPS drug reimbursement rate at ASP plus 4%

Traynor, Kate
December 2009
American Journal of Health-System Pharmacy;12/15/2009, Vol. 66 Issue 24, p2154
Academic Journal
The article discusses the plan of the U.S. Centers for Medicare and Medicaid Services (CMS) to keep drug reimbursement rate of the outpatient prospective payment system (OPPS) at average sales price (ASP) plus 4% in 2010. Justine Coffey of the American Society of Health-System Pharmacists (ASHP) said that ASHP is unhappy with CMS's proposal. It says that the proposal stated that hospitals will need to take on some responsibilities in submitting more accurate data.


Related Articles

  • CMS Issues Ruling on Retisert.  // Review of Ophthalmology;Nov2005, Vol. 12 Issue 11, p11 

    Reports that Bausch & Lomb Inc.'s single-indication orphan drug Retisert that is compose of fluocinolone acetonide intravitreal implant has been approved by the Centers for Medicare & Medicaid to be eligible for Medicare Hospital Outpatient Prospective Payment System effective October 1, 2005 in...

  • WEEK IN WASHINGTON.  // BioWorld Insight;7/25/2011, Vol. 19 Issue 30, p6 

    The article offers information on the proposed guidance of the U.S. Food & Drug Administration (FDA) for companion diagnostics and medical applications and on the initiative of the Centers for Medicare & Medicaid Services for a national benchmark to set prescription drug reimbursement.

  • Regulatory scorecard: What is happening now!  // Pharmacy Today;Dec2011, Vol. 17 Issue 12, p20 

    The article offers information on the status of several proposed medical policies in the U.S. which have request for information including U.S. Centers for Medicare and Medicaid Services (CMS), U.S. Institute of Medicine (IOM), and U.S. Drug Enforcement Administration (DEA).

  • implementing the MMA. Wilensky, Gail R. // hfm (Healthcare Financial Management);Jun2004, Vol. 58 Issue 6, p30 

    Examines challenges faced by the United States Centers for Medicare and Medicaid Services (CMS) related to the implementation of the Medicare Prescription Drug, Improvement, and Modernization Act. Encouragement of private plan participation in Medicare; Changes to Part B outpatient drug...

  • CMS Encourages Physicians To E-Prescribe.  // Getting Paid in Behavioral Healthcare;Jul2007, Vol. 12 Issue 7, p8 

    The article reports on a new policy that encourages physicians to send electronic prescribing when sending prescription orders in the U.S. Proposed by Centers for Medicare and Medicaid Services (CMS) on June 29, 2007, it suggests the withdrawal of current exemption for computer-generated faxes...

  • CMS Is Now Accepting Hardship Exemption Applications to Avoid 2013 E-Prescribing Penalty.  // Part B Insider;Apr2012, Vol. 13 Issue 15, p113 

    The article announces that the U.S. Centers for Medicare and Medicaid Services (CMS) is accepting hardship exemptions to avoid electronic prescribing penalty in 2013. The criteria for the eligibility to apply for an exemption are outlined. The deadline for the submission of hardship applications...

  • Retina specialists could face compensation issues regarding bevacizumab, other procedures. Bechtel, Bryan // Ocular Surgery News;11/10/2009, Vol. 27 Issue 21, p22 

    This article reports on the passage of a new rule by the U.S. Centers for Medicare and Medicaid Services (CMS) in October 2009 that mandates compensation for bevacizumab based on average price of the drug. The new rate does not consider associated expenses, says ophthalmologist Trexler M....

  • CMS Finalizes Four New Ways to Avoid 2012 E-Prescribing Payment Penalty.  // Part B Insider;10/1/2011, Vol. 12 Issue 31, p241 

    The article reports that the U.S. Centers for Medicaid & Medical Services (CMS) has finalized ways to avoid electronic prescribing payment penalty by offering exemptions that will kick in 2012 in the U.S. Eligible professionals (EPs) can avoid the adjustment if they meet the criteria which...

  • CMS Revises Medicare Advantage, Part D Policies.  // Aging News Alert;1/16/2009, p22 

    The article reports that the U.S. Centers for Medicare & Medicaid Services (CMS) will accept comments until March 17, 2009 on an interim rule regarding Medicare Advantage (MA), prescription drug programs' drug formulary and protected classes policies. The interim rule makes conforming changes to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics